Listen
ZORYON (méthadone)
ANALGESIA
Opinions on drugs -
Posted on
Mar 24 2020
Reason for request
Inclusion
Substantial clinical benefit but no demonstrated clinical added value in the treatment of chronic cancer pain not adequately relieved by other step 3 opioids
- ZORYON has an MA in the chronic treatment of moderate to severe cancer pain in patients not adequately relieved by other step 3 opioids.
- Methadone has been used off-label for numerous years in the treatment of patients with chronic cancer pain. Treatment with ZORYON (methadone) may be initiated in these patients during a step 3 opioid rotation.
- The pharmacokinetic characteristics and safety data for methadone call for caution when initiating treatment; initiation should be performed in a hospital setting by a pain management or palliative care team experienced in the use of the product.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Documents
English version
Contact Us
Évaluation des médicaments
